Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events
Executive Summary
No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.
You may also be interested in...
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
Novo Eyes Global-First Japan Approval For Concizumab
Novo Nordisk has filed for the approval of its hemophilia A/B contender concizumab in Japan, which could become the first market globally for the TFPI inhibitor. The company sees dosing convenience as a potential strong advantage in the market, where there are relatively few options for hemophilia B available.
Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia
Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.